Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
neurosteroid compound
- Development stage
- Unknown
- Lead developer
- Oragenics
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Parenteral, Transdermal, Inhalation, Intracerebral, Topical
01
Overview
A patented neurosteroid compound is being developed by a 50/50 joint venture between Odyssey Group International and Prevacus. This compound is intended for the treatment of amyotrophic lateral sclerosis (ALS) and Niemann-Pick disease. Odyssey Group International is responsible for funding the joint venture through Phase 1 clinical trials for this drug.
- Other names
- neurosteroidpatented chemical compound
02
Targets
GABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on neurosteroid compound.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on neurosteroid compound.